Pfizer commences work on new Missouri research facility

Pfizer has announced the commencement of construction work on a new research and development facility in Chesterfield, Missouri.

The state-of-the art research and process development facility at Chesterfield Parkway will be owned by Pfizer and will bring together more than 450 employees who are currently spread across multiple locations leased by Pfizer in the St Louis area.

An additional 80 employees will be hired over the coming years to support research at the site, construction of which is expected to be complete by mid-2019.

When complete, the facility will provide around 295,000 sq ft of research and development space to house Pfizer's biotherapeutics pharmaceutical sciences group, which is responsible for advancing the company's biologics, vaccines and gene therapy portfolio.

Key features include a floor plan that provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces, and enhanced conferencing technologies to further facilitate team-based working.

John Ludwig, senior vice-president of biotherapeutics pharmaceutical sciences for Pfizer, said: "We've been proud to call Missouri home since 2002. During this time, we've benefitted from the excellent life sciences workforce based in Missouri, and also from a strong partnership with the state."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.